The Pulmonary Arterial Hypertension drugs in development market research report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pulmonary Arterial Hypertension. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued products.
GlobalData tracks 126 drugs in development for Pulmonary Arterial Hypertension by 104 companies/universities/institutes. The top development phase for Pulmonary Arterial Hypertension is preclinical with 52 drugs in that stage. The Pulmonary Arterial Hypertension pipeline has 117 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Pulmonary Arterial Hypertension pipeline products market are: Johnson & Johnson, United Therapeutics and ATXA Therapeutics.
The key targets in the Pulmonary Arterial Hypertension pipeline products market include Prostacyclin Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, and Platelet Derived Growth Factor Receptor.
The key mechanisms of action in the Pulmonary Arterial Hypertension pipeline product include Prostacyclin Receptor Agonist with 13 drugs in Pre-Registration. The Pulmonary Arterial Hypertension pipeline products include 13 routes of administration with the top ROA being Oral and 16 key molecule types in the Pulmonary Arterial Hypertension pipeline products market including Small Molecule, and Monoclonal Antibody.
Pulmonary Arterial Hypertension overview
Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea, and other diseases, including congenital heart disease, lung disease, liver disease, and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids, and calcium channel blockers.
For a complete picture of Pulmonary Arterial Hypertension’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
